Navigation Links
LeMaitre Vascular Launches Next-Generation Stent Graft Delivery System
Date:11/16/2007

BURLINGTON, Mass., Nov. 16 /PRNewswire-FirstCall/ -- LeMaitre Vascular, Inc. (Nasdaq: LMAT) today announced the commercial launch of the TT(TM) Tortuous Tracker Delivery System, the next-generation introducer for LeMaitre Vascular's EndoFit(R) and UniFit(TM) Aortic Stent Graft product lines. The new delivery system will be sold beginning on Monday, November 19th, in the European Union and other select markets outside of the United States.

The TT system is designed to simplify stent graft implants by requiring reduced deployment force, providing the physician with increased control over placement of the stent graft in the aorta. The TT system offers better flexibility and an improved coating to increase maneuverability through blood vessels and a three-part valve system to minimize blood loss during the medical procedure. The TT system also provides better visualization during the procedure and a more ergonomic design.

"The TT system should improve the ease of use and therefore the performance of our endovascular stent grafts," said Ryan Connelly, Director, Research & Development of LeMaitre Vascular. "Since we acquired our stent graft product lines in 2005, we have carefully studied what vascular surgeons need to successfully deliver and deploy aortic stent grafts. The new TT system gives them what they have been asking for, which will enable better clinical results and improve patients' lives."

The TT system has already been used by physicians in over a dozen procedures designed to provide the company with pre-launch clinical feedback.

"I was very pleased with the flexibility of the device and its ability to navigate tortuous vessels," said Thomas Larzon, MD, Director of the EndoVascular Unit
'/>"/>

SOURCE LeMaitre Vascular, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. LeMaitre Vascular to Start Italian Sales Force
2. LeMaitre Vascular to Participate at CIBC 18th Annual Healthcare Conference
3. LeMaitre Vascular Reports Q3 2007 Revenue of $10.1 Million, a 19% Increase
4. LeMaitre Vascular to Participate at Canaccord Adams Inaugural Cardiovascular Conference
5. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
6. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
7. Pot bellies linked to early signs of cardiovascular disease
8. Air pollution linked to cardiovascular risk indices in healthy young adults
9. Environmental stress probed in cardiovascular disease, diabetes
10. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
11. American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... schools need to work together to stop abusive beh...HealthDay News) -- Behavior that was once dismisse...ng. , And as mounting research shows the negati...l-health professionals, schools, parents and even ...bat this threatening behavior. , "Bullying sho...
(Date:11/21/2008)... 2008)The University of Texas Health Science Cente...xcellence in Aging Studies (TEXAS), to promote ger...ous $2 million award from the Donald W. Reynolds F...This will allow us to teach geriatric medicine pri...tudent to practicing physicians. With the reach of...
(Date:11/21/2008)...v. 21 The Providence Ser...d that Craig A. Norris, the Company,s,Chief Opera...Board of,Directors. Mr. Norris, appointment fill...of Steven I. Geringer and returns the board to six...ttee of the Board. , Mr. Norris, age 41, ha...
(Date:11/21/2008)...zel proved effective against Lennox-Gastaut syndro...-- A new drug called Banzel (rufinamide) has been ... form of epilepsy called Lennox-Gastaut syndrome, ...iday. , The approval was based on results of a ...ges 4 to 30. Compared to patients who took a place...
Breaking Medicine News(10 mins):Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2
...archers at Weill Cornell Medical College could pro...inds. The compound, called SS31, is able to cross...stress molecule recently linked to stroke-related ...eriments, we found that exposing mice to SS31 afte...
...apore have warned people that at least 90 people h...ast five years// in the island republic. They said... clams, and mussels among others. The warning cam...ly man who was bitten by a crab when he was cleani...
...e discovering that some foods and supplements do h...ern// world’s deadliest killer- the ‘big C’. At th...Society, a one-day symposium, more than a dozen re...l be presented. Selected highlights are shown bel...
...ut most of life’s best inventions did sound strang...ics. Cardiologist Michael Barrett of Temple Uni...a study detailing his experiments with ‘recorded h...American College of Cardiology. According to Bar...
Other Medicine News:Health News:Antioxidant Molecule Could Help Minimize Stroke-Linked Brain Damage 2Health News:Emboldened Warriors-Cancer Fighting Foods 2Health News:Emboldened Warriors-Cancer Fighting Foods 3Health News:Heartbeats on IPods - Being ‘cool’ can Help Doctors t 2
(Date:11/19/2008)...ers $5 Million Payment from Roche- , , MONT...ry Pharmaceuticals Corp. (Nasdaq: MEMY ) today a...for its Phase 2 trial of R3487/MEM 3454, its lead ...mpairment associated with schizophrenia (CIAS). T...e 2 trial, triggering a $5.0 million payment from ...
(Date:11/18/2008)... www.christmasseals.org to learn more, make a don...WASHINGTON, Nov. 17 Mil...s month, courtesy of the American Lung Association...nnual fundraising tradition dating back to 1907 wh...erculosis. , , "Most Americans alive toda...
(Date:11/18/2008)...WNE, Va., Nov. 18 Forty...ered at a November national forum to consider cutt...lic health and national economy from outbreaks of ...nced today. , , Among those innovations: ,... American kitchen table that detects highly contag...
(Date:11/18/2008)...ized study will enroll newly diagnosed, elderly AM...Newswire/ -- Celator Pharmaceuticals today announc...ndomized Phase 2 clinical study of CPX-351 (Cytara...with newly diagnosed acute myeloid leukemia (AML).... Feldman, MD at the Weill Medical College of Corn...
Breaking Medicine Technology:Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3American Lung Association Celebrates 101st Annual Christmas Seals Campaign 242 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3Life under the laser 4630 1Life under the laser 4630 2Baxa Corporation Named to Inc 5000 for Second Consecutive Year as One of the Fastest Growing Private Companies in the US 7375 1Baxa Corporation Named to Inc 5000 for Second Consecutive Year as One of the Fastest Growing Private Companies in the US 7375 2Journal of Nutrition Health and Aging to be published by Springer 4626 1Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use of HemosIL 28R 29 D Dimer Assay 7367 1Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use of HemosIL 28R 29 D Dimer Assay 7367 2
... Substantial,Reduction of Disease Activity in Pati...rosis , Combination Treatment With Antibiotic Furt... KANSAS CITY, Mo, May 4, 2007 - New data from a ra...tion of Copaxone,(glatiramer acetate injection) al...1 Gadolinium (Gd)-enhancing lesions of the,brain b...
...n Multiple,Sclerosis May Include Direct Activity i... FTY720 stimulates cells,that may help reduce neur...ed by multiple sclerosis , · Separately, an... II clinical study found that the proportion of,pa...lower in the,FTY720 groups compared to placebo , &...
Other Medicine Technology:Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 6Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 7Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 8Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 9Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 10Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 11Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 12Data to be presented at AAN Meeting -Study results of drug,candidate for MS 2Data to be presented at AAN Meeting -Study results of drug,candidate for MS 3Data to be presented at AAN Meeting -Study results of drug,candidate for MS 4Data to be presented at AAN Meeting -Study results of drug,candidate for MS 5Data to be presented at AAN Meeting -Study results of drug,candidate for MS 6Data to be presented at AAN Meeting -Study results of drug,candidate for MS 7Data to be presented at AAN Meeting -Study results of drug,candidate for MS 8Data to be presented at AAN Meeting -Study results of drug,candidate for MS 9
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
Medicine Products: